BMS/Pfizer's Eliquis better than Lovenox, but comparison with Pradaxa and Xarelto not clear, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the health technology assessment body for England and Wales, has fast tracked Bristol-Myers Squibb's oral direct Factor Xa inhibitor, Eliquis (apixaban), through its appraisal process and has published final draft guidance recommending it for preventing blood clots after hip and knee surgery. The institute says it is both cheaper and more clinically effective than Sanofi's Lovenox, (enoxaparin). However, the jury is still out on how it compares to Boehringer Ingelheim's Pradaxa (dabigatran) and Bayer's Xarelto (rivaroxaban), partly because of the way in which the comparison was conducted.